Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free CINGW Stock Alerts

Cingulate (CINGW) Competitors

$0.03 +0.00 (+6.67%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CINGW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Cingulate stock or one of its competitors? MarketBeat compares Cingulate with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cingulate include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Cingulate compare to Ainos?

Ainos (NASDAQ:AIMDW) and Cingulate (NASDAQ:CINGW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Ainos and Ainos both had 3 articles in the media. Cingulate's average media sentiment score of 0.96 beat Ainos' score of 0.62 indicating that Cingulate is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ainos
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cingulate
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Cingulate N/A N/A N/A

Summary

Ainos and Cingulate tied by winning 1 of the 2 factors compared between the two stocks.

How does Cingulate compare to Alvotech?

Cingulate (NASDAQ:CINGW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Cingulate had 1 more articles in the media than Alvotech. MarketBeat recorded 3 mentions for Cingulate and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.44 beat Cingulate's score of 0.96 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Positive
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Summary

Alvotech beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Cingulate compare to Aravive?

Cingulate (NASDAQ:CINGW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cingulate had 3 more articles in the media than Aravive. MarketBeat recorded 3 mentions for Cingulate and 0 mentions for Aravive. Cingulate's average media sentiment score of 0.96 beat Aravive's score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Aravive Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Aravive N/A N/A N/A

Summary

Cingulate and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Cingulate compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Cingulate (NASDAQ:CINGW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Cingulate had 3 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 3 mentions for Cingulate and 0 mentions for Atlantic Coastal Acquisition Corp. II. Cingulate's average media sentiment score of 0.96 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Cingulate N/A N/A N/A

Summary

Cingulate beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Cingulate compare to Biofrontera?

Cingulate (NASDAQ:CINGW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for Cingulate and 2 mentions for Biofrontera. Cingulate's average media sentiment score of 0.96 beat Biofrontera's score of 0.43 indicating that Cingulate is being referred to more favorably in the media.

Company Overall Sentiment
Cingulate Positive
Biofrontera Neutral

Summary

Cingulate beats Biofrontera on 2 of the 3 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CINGW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CINGW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CINGW vs. The Competition

Export
MetricCingulateBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$456.34M$6.25B$12.42B
Dividend YieldN/A3.87%2.69%5.29%
P/E RatioN/A3.1622.3024.19
Price / SalesN/A6,509.16581.37138.33
Price / CashN/A13.1342.3157.88
Price / BookN/A84.759.846.72
Net IncomeN/A-$96.07M$3.57B$337.19M
7 Day PerformanceN/A-0.06%-1.16%0.48%
1 Month PerformanceN/A0.75%3.85%5.06%
1 Year PerformanceN/A74.33%27.40%34.27%

Cingulate Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CINGW
Cingulate
N/A$0.03
+2.7%		N/A-49.0%$0.00N/AN/A20
AIMDW
Ainos
N/A$0.06
-13.3%		N/A-15.3%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.19
flat		N/A-93.4%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-86.1%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CINGW) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel